Turvill J - Search Results

1

Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease.

Turvill J, Rook L, Rawle M, Robins G, Smale S, Kant P, Phillips A. Turvill J, et al. Frontline Gastroenterol. 2017 Jul;8(3):183-188. doi: 10.1136/flgastro-2016-100780. Epub 2017 Jan 30. Frontline Gastroenterol. 2017. PMID: 28839907 Free PMC article.

2

Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway.

Turvill J, Turnock D, Holmes H, Jones A, Mclaughlan E, Hilton V, Marriott S. Turvill J, et al. Frontline Gastroenterol. 2018 Oct;9(4):285-294. doi: 10.1136/flgastro-2018-100962. Epub 2018 Jun 7. Frontline Gastroenterol. 2018. PMID: 30245791 Free PMC article.

3

Audit of the impact of the York faecal calprotectin care pathway on colonoscopy activity.

Turvill J, Turnock D. Turvill J, et al. Frontline Gastroenterol. 2019 Oct 24;11(4):285-289. doi: 10.1136/flgastro-2019-101315. eCollection 2020. Frontline Gastroenterol. 2019. PMID: 32587672 Free PMC article.

4

Getting the best out of faecal immunochemical tests and faecal calprotectin.

Chuter C, Keding A, Holmes H, Turnock D, Turvill J. Chuter C, et al. Among authors: turvill j. Frontline Gastroenterol. 2019 Dec 24;11(5):414-416. doi: 10.1136/flgastro-2019-101381. eCollection 2020. Frontline Gastroenterol. 2019. PMID: 32884634 Free PMC article. No abstract available.

5

Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer.

Turvill J, Mellen S, Jeffery L, Bevan S, Keding A, Turnock D. Turvill J, et al. Scand J Gastroenterol. 2018 Dec;53(12):1526-1534. doi: 10.1080/00365521.2018.1539761. Epub 2019 Jan 8. Scand J Gastroenterol. 2018. PMID: 30621475

6

Evaluation of a faecal calprotectin care pathway for use in primary care.

Turvill J, O'Connell S, Brooks A, Bradley-Wood K, Laing J, Thiagarajan S, Hammond D, Turnock D, Jones A, Sood R, Ford A. Turvill J, et al. Prim Health Care Res Dev. 2016 Sep;17(5):428-36. doi: 10.1017/S1463423616000049. Epub 2016 Feb 22. Prim Health Care Res Dev. 2016. PMID: 26899214

7

Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy.

Turvill J. Turvill J. Frontline Gastroenterol. 2014 Jul;5(3):167-175. doi: 10.1136/flgastro-2014-100441. Epub 2014 Apr 16. Frontline Gastroenterol. 2014. PMID: 28839766 Free PMC article.

8

Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study.

Turvill J, Aghahoseini A, Sivarajasingham N, Abbas K, Choudhry M, Polyzois K, Lasithiotakis K, Volanaki D, Kim B, Langlands F, Andrew H, Roos J, Mellen S, Turnock D, Jones A. Turvill J, et al. Br J Gen Pract. 2016 Jul;66(648):e499-506. doi: 10.3399/bjgp16X685645. Epub 2016 Jun 6. Br J Gen Pract. 2016. PMID: 27266863 Free PMC article.

9

High negative predictive value of a normal faecal calprotectin in patients with symptomatic intestinal disease.

Turvill J. Turvill J. Frontline Gastroenterol. 2012 Jan;3(1):21-28. doi: 10.1136/flgastro-2011-100011. Epub 2011 Sep 19. Frontline Gastroenterol. 2012. PMID: 28839626 Free PMC article.

10

Evaluation of the Cost-Utility of the York Faecal Calprotectin Care Pathway.

Holmes H, McMaster J, Davies H, Vaines V, Turvill J. Holmes H, et al. Among authors: turvill j. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr;22(3):521-528. doi: 10.1080/14737167.2020.1751613. Epub 2020 Apr 19. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 32249622

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page